BRIEF-Autodoc IPO Price Range Eur 58.00 To Eur 61.00 Per Share - Bookrunner-March 2024-www.financetom.com

BRIEF-Autodoc IPO Price Range Eur 58.00 To Eur 61.00 Per Share - Bookrunner

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Autodoc IPO Price Range Eur 58.00 To Eur 61.00 Per Share - Bookrunner

Jun 17, 2025 12:57 AM

June 17 (Reuters) -

* AUTODOC IPO - BOOKS OPEN - BOOKRUNNER

* IPO PRICE RANGE: EUR 58.00 - EUR 61.00 PER SHARE -

BOOKRUNNER

* IPO BASE DEAL SIZE: 6,608,696 SHARES / C.EUR 383M - EUR

403M -

BOOKRUNNER

* IPO TOTAL DEAL SIZE: 7,600,000 SHARES / C.EUR 441M - EUR

464M -

BOOKRUNNER

(Gdansk Newsroom)

Previous page： FMC Partners With Optibrium to Accelerate Pipeline Next page： Franklin Electric Names Joe Ruzynski CEO

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

FMC Partners With Optibrium to Accelerate Pipeline

May 14, 2024

08:35 AM EDT, 05/14/2024 (MT Newswires) -- FMC Corporation ( FMC ) said Tuesday it is working with Optibrium to discover small molecules that can help with crop protection. Financial terms of the partnership were not disclosed. The agreement is part of FMC's strategic plan to accelerate the discovery and commercialization of the agriculture science company's pipeline. FMC will use...

Franklin Electric Names Joe Ruzynski CEO

May 14, 2024

08:38 AM EDT, 05/14/2024 (MT Newswires) -- Franklin Electric ( FELE ) said Tuesday it named Joe Ruzynski chief executive officer and a member of its board, effective July 1. Ruzynski, 49, succeeds Gregg Sengstack, chief executive since 2014 and chair since 2015, who will continue as executive chair of the water and energy technology firm's board. Ruzynski previously served...

US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine

May 14, 2024

May 14 (Reuters) - The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies' ( DVAX ) hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday. ...

Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell

May 14, 2024

08:30 AM EDT, 05/14/2024 (MT Newswires) -- Profound Medical ( PROF ) said Tuesday that it received US Food and Drug Administration clearance for its TULSA-AI Contouring Assistant for use with its TULSA-PRO system to treat prostate disease. The medical device company said that TULSA uses pixel-by-pixel precision and sound technology to kill diseased prostate tissue without damaging urinary or...